(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 April 2011 (14.04.2011)

PCT

(10) International Publication Number
WO 2011/042368 A1

(51) International Patent Classification:
A61K 31/416 (2006.01) *C07D 401/04* (2006.01)

(21) International Application Number:
PCT/EP2010/064648

(22) International Filing Date:
1 October 2010 (01.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09172304.9 6 October 2009 (06.10.2009) EP

(71) Applicant *(for all designated States except US)*: **Bayer Schering Pharma Aktiengesellschaft** [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MICHELS, Martin** [DE/DE]; Hoffnungsthaler Str. 9, 51109 Köln (DE). **FOLLMANN, Markus** [DE/DE]; Ringstr. 61, 42489 Wülfrath (DE). **VAKALOPOULOS, Alexandros** [GR/DE]; Heinrich-Heine-Str. 79a, 40721 Hilden (DE). **ZIMMERMANN, Katja** [DE/DE]; Bockumerstr. 370 b, 40489 Düsseldorf (DE). **TEUSCH, Nicole** [DE/DE]; Ringstr. 61, 42489 Wülfrath (DE). **LOBELL, Mario** [DE/DE]; Am Eigenbach 16, 42113 Wuppertal (DE). **BIERER, Donald** [US/US]; 46 Hilltop Road, Bethany, Connecticut 06524 (US). **ENGEL, Karen** [DE/DE]; Goethestr. 55, 42327 Wuppertal (DE). **KISSEL, Maria** [DE/DE]; Katernberger Str. 246, 42113 Wuppertal (DE).

(74) Common Representative: **Bayer Schering Pharma Aktiengesellschaft**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/042368 A1

(54) **Title**: FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1*H*-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF

(57) **Abstract**: The present invention relates to novel fluoro-substituted 3,5-dicyano-4-(1*H*-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.